The Bull Rankings scorecard — our quality-growth score is 83.8 / 100, built from three pillars scored 0–100: Quality 88, Growth 94, Value 72 (valuation is judged against sector peers). At today's price, our reverse-DCF read says the market is implicitly betting on free-cash-flow growth of about 28% a year next year, fading to 3% a year by year ten — a gauge of how much optimism is already in the stock.
The thesis
CareDx is a high‑growth, high‑quality compounder that the market prices for somewhat slower growth than it is delivering. As of the quarter ended June 30 2026 the stock trades at $38.1, just 6 % below its 52‑week high of $40.47, while revenue surged 34.4% YoY. Our model awards an 83.8/100 quality‑growth score, driven by a Growth pillar of 94 and a Quality pillar of 88. The softest is a Value pillar of 72, which still sits on the cheap side of peers. The reverse‑DCF built into the Bull Rankings model implies the market expects ~28% annual free‑cash‑flow growth (in year one, slowing to 3% a year by year ten). That assumption sits below the 34.4% revenue growth we see now, meaning the price already allows for some slowdown in cash generation. With a ROE of 26.1% and profit margin of 24.2%, the business is turning profits at a rate that can fund that growth without external capital. In short, the strongest pillar (Growth) carries the bull case, and even the softest, Value, sits on the cheap side of peers. The thesis: CDNA’s quality and growth look underpriced, as long as the implied 28% FCF trajectory proves realistic.
What the business actually is
CareDx sells transplant‑monitoring diagnostics that let clinicians detect organ injury before it becomes irreversible. Its flagship AlloSure Kidney measures donor‑derived cell‑free DNA (dd‑cfDNA) to flag early rejection in kidney recipients. The AlloMap Heart gene‑expression panel and AlloSure Heart dd‑cfDNA test serve heart transplants, while AlloSure Lung does the same for lung grafts. The HeartCare platform interprets these signals into actionable categories—immune quiescence, active injury, acute cellular rejection, and antibody‑mediated rejection—giving physicians a clear roadmap. The primary customers are transplant centers and hospital labs across the United States and abroad, with the kidney segment historically delivering the bulk of revenue and now the lung and heart lines accelerating.
Why it can keep compounding
Margins of 24.2% and a ROE of 26.1% show the business extracts strong returns on capital, a hallmark of a quality franchise. The moat stems from the proprietary dd‑cfDNA technology, which requires sophisticated assay development and regulatory clearance—barriers that keep competitors at bay. Moreover, the data‑rich HeartCare analytics create a sticky relationship with clinicians; once a center adopts the platform, switching costs are high because longitudinal patient data are embedded in the system. Our model flags stock buybacks as a positive signal, indicating management believes the shares are undervalued relative to intrinsic cash generation. With a debt‑to‑equity of just 0.08, the balance sheet is lean, giving the company room to reinvest in R&D or expand into new organ markets without diluting shareholders.
The valuation question
At $38.1 the stock trades at a price‑to‑sales multiple of 4.3, which sits near the healthcare median. The reverse‑DCF suggests the market is pricing in ~28% yearly free‑cash‑flow growth (in year one, slowing to 3% a year by year ten). Compare that to the 34.4% YoY revenue growth the company just reported; the implied FCF growth is lower than the current revenue trajectory, implying the market already allows for some slowdown. However, the Value pillar of 72 signals that, relative to peers, the stock is on the cheap side, even as investors bet on continued high‑margin expansion and the upcoming rollout of AlloSure Lung. If the company can keep margins near 24% while scaling, the 28% FCF assumption is plausible. If margins erode or growth slows, the price will look overvalued.
The bear case
Skeptics point to the beta of 2.43, meaning the stock is far more volatile than the market—any miss on growth could trigger outsized downside. The analyst consensus 1‑yr target of $35.4 sits below today’s price, indicating that even the sell‑side expects a modest correction. Recent news that BlackRock disclosed a 9% beneficial stake (Stock Titan) could be interpreted as a signal that a large institutional player sees upside, but it also raises the specter of a future sell‑down that could pressure the share price. The weakest pillar—Value—still sits on the cheap side, but a single quarter of slower revenue growth or a margin dip would make the 28% implied FCF growth look unattainable, prompting a sharp re‑rating.
What would change our mind
First, a quarterly revenue growth slowdown to below 20% would break the link between current growth and the 28% FCF assumption, flipping the thesis to bearish. Second, if profit margin fell under 20%—a drop of more than 4 percentage points—our Quality score would erode. Third, any increase in debt‑to‑equity above 0.2 would signal balance‑sheet strain, undermining the buy‑back signal and raising borrowing costs. Until one of those triggers appears, the upside from a high‑quality, high‑growth franchise outweighs the risks.